Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic
Purdue University News
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
Read MoreSeptember 23, 2024